Global health innovators recognised with Abu Dhabi Global Health Week Innovation Awards for transformative impact
The diverse range of applicants underscore the pivotal role in encouraging international collaboration and demonstrates Abu Dhabi's commitment to nurturing a thriving ecosystem to redefine global health
Abu Dhabi, UAE: Abu Dhabi Global Health Week (ADGHW) today honoured exceptional individuals and institutions from around the world whose innovative contributions are advancing the future of health. Winners of the ADGHW Innovation Awards 2025 were recognised for pioneering solutions in digital health, biotechnology, and diagnostics, receiving global recognition and a share of the $200,000 prize fund.
With a total of 91 submissions received from global and local individuals and institutions, the ADGHW Innovation Awards, sponsored by e& and PureHealth, welcomed entries that address critical health challenges across digital health, pharmaceutical and biotechnology innovations, and medical devices and diagnostics. Winners were selected following a rigorous review process led by a distinguished panel of global health experts, policymakers, and technology leaders.
ADGHW Innovation Awards recipients include:
The Individual Category was awarded to the Nobel Laureate in Physiology or Medicine, Dr. Ardem Patapoutian from the Scripps Research Institute for discovering novel molecular targets involved in pain perception. His work is unlocking new therapeutic pathways to treat chronic and neuropathic pain, significantly advancing personalised medicine and neuroscience.
Runners-up for this category include Hesham A. Abdullah from GlaxoSmithKline (GSK) recognised for his impactful oncology research and contributions to healthcare innovation in the region; and Kourosh Lotfi from Sheikh Shakhbout Medical City for advancing 3D bioprinting technologies for personalised regenerative medicine.
The Global Institute Category was jointly awarded to the Children's Hospital of Philadelphia for development of prenatal therapeutic gene editing technologies and the University of Pennsylvania for its pioneering work in mRNA platform technology, the foundation of several next-generation vaccines.
Runners-up for this category include Children's National Hospital for its StrepApp, an artificial intelligence (AI)-driven diagnostic tool enhancing the accuracy and efficiency of paediatric care; Eli Lilly and Company for revolutionising obesity care through the first dual GIP/GLP-1 treatment, redefining approaches to metabolic diseases; and Neo Q Quality in Imaging GmbH for RadioReport Automatic AI, transforming radiology reporting through automation and precision.
The Regional Institute Category was awarded to the King Faisal Specialist Hospital & Research Centre for revolutionising organ transplantation through robotic-assisted surgery. The hospital's innovative use of robotics enhances surgical precision, reduces recovery time, and sets a new benchmark for transplant care in the Middle East and beyond.
Runners-up for this category include amplifai health for its AI-based thermal camera to screen diabetic foot ulcers, enabling early detection and proactive care to reduce complications; Proteinea for its AI-enabled Protein Engineering Platform designed to accelerate next-generation biotherapeutic development; and Pioneera Biosciences for BestCAR, an allogeneic CAR-NK cell therapy leveraging mRNA-LNP technology to target CD19 in haematologic malignancies.
The Local Institute Category was awarded to BioSapien Inc. for its MediChip, a novel drug delivery platform that localises treatment to targeted areas, reducing systemic side effects and enhancing efficacy. The technology represents a significant leap forward in precision therapeutics and patient-centric care.
Runners-up for this category include New York University Abu Dhabi for LAMINATE MS, an advanced neuroimaging platform to improve diagnosis and treatment of multiple sclerosis; Sheikh Shakhbout Medical City for CHESS-Osteoporosis, a multi-centre validation trial driving innovation in bone health screening; EpiBone, Ltd. for its AI-powered living skeletal implants, redefining bone repair and personalised orthopaedic care; and Sheikh Shakhbout Medical City for advancing haematological diagnostics, enhancing AI models through multimodal data integration and clinical validation.
The award ceremony commenced with opening remarks by H.E. Dr. Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi, who underscored the award's pivotal role in recognising excellence, fostering innovation, and accelerating progress across the healthcare sector. The event brought together senior government officials, healthcare leaders, and industry partners, including H.E. Dr. Jaleela bint Al-Sayed Jawad Hasan, Minister of Health of the Kingdom of Bahrain; H.E. Dr. Mikheil Sarjveladze, Minister of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia; Shaista Asif, Group Chief Executive Officer of PureHealth; Dr. Patrick Horber, President, International of Novartis; and Jacob Thaysen, Chief Executive Officer of Illumina.
Commenting on the winners' announcement, H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of DoH, said: 'We are delighted to honour these trailblazers from around the world. Their achievements show how powerful innovation can be in changing the global health landscape and highlight what's possible when we work together. By celebrating these breakthroughs, we're not only recognising what's been accomplished today, we are also paving the way for a healthier tomorrow for all, where everyone enjoys well-being and a long, healthy life.'
Submissions were evaluated based on originality, impact, scalability, and sustainability. The rigorous assessment process was overseen by a panel of esteemed experts in healthcare, digital health, and public policy including Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at DoH; Professor Shafi Ahmed, multi-award-winning surgeon, teacher, futurist, innovator and entrepreneur; John Nosta, president of NostaLab, Lina Shadid, Middle East Health Industries Lead and Zubin Daruwalla, Asia Pacific Health Industries Lead at PwC.
'The ADGHW Innovation Awards exemplify the transformative power of collaboration and innovation in addressing global health challenges with creativity, rigour, and purpose. The diversity and ingenuity of the application submissions highlight Abu Dhabi's role in boosting an ecosystem that drives advancements in healthcare. At PwC, we are proud to support this initiative and contribute to shaping a future where innovation is both encouraged and celebrated,' stated Lina Shadid, Middle East Health Industries Lead at PwC.
The diverse group of applicants underscores ADGHW's pivotal role in enhancing international collaboration and demonstrates Abu Dhabi's commitment to nurturing a thriving ecosystem that drives advancement of the global health sector.
In a first for the awards, an AI assistant was also integrated into the review process, supporting the jury by surfacing patterns, providing comparative insights, and complementing human expertise during deliberations. This hybrid model reflects ADGHW's commitment to harnessing the potential of emerging technologies to drive fairness, transparency, and efficiency in the evaluation of innovative ideas.
ADGHW is a major government initiative from DoH and serves as a platform for innovation and collaboration under the theme 'Towards Longevity: Redefining Health and Well-being.' It places a strong emphasis on community-driven health and well-being, with a proactive approach centred around preventive, personalised, and holistic care.
Four core themes will guide discussions and initiatives: Longevity and Precision Health; Health System Resilience & Sustainability; Digital Health & AI; and Investment in Life Sciences. By convening diverse stakeholders from around the world, ADGHW is a community without borders that seeks to advance the future of health and well-being.
About Abu Dhabi Global Health Week:
Abu Dhabi Global Health Week (ADGHW) is a major government-led initiative by the Department of Health – Abu Dhabi (DoH). It drives transformative innovation and collaboration under the theme 'Towards Longevity: Redefining Health and Well-being'. ADGHW serves as a year-round 'always-on' platform with a proactive approach centred around preventive, personalised, and holistic care. Held with and for the world, ADGHW is a platform for open, inclusive exchange, and joint action.
ADGHW welcomes entrepreneurs, policymakers, researchers, innovators, and investors to transform ideas into action, and collaborate around topics like advancing precision care and building a resilient technology-driven ecosystem. ADGHW 2025 proudly collaborates with key strategic partners, including Foundation Partner, M42 and Global Health and Longevity Champion, PureHealth. Additional exhibitors and sponsors include Burjeel, GSK, Johnson & Johnson, Lilly, Microsoft, Novo Nordisk, Viatris, Novartis, Roche, Cleveland Clinic Abu Dhabi, Deloitte, Gilead, Juvenescence, NYU Abu Dhabi and Pfizer, united in their commitment to advancing the future of healthcare and life sciences.
For more information on ADGHW, visit https://www.adghw.com/
For media registration visit, https://www.adghw.com/forms/media-registration/
For media inquiries or interview opportunities, please contact:
Maroun Farah, Senior Media Relations Manager, Weber Shandwick
E: mfarah@webershandwick.com
About the Department of Health – Abu Dhabi (DoH):
The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH's unwavering commitment to predicting, preventing and personalising healthcare for every individual.
For further information on DOH, visit https://www.doh.gov.ae/ and follow on X, Instagram, Facebook, LinkedIn and YouTube.
For media inquiries, please contact:
Mariam Al Marzooqi
E: msalmarzooqi@doh.gov.ae
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
a day ago
- Zawya
On World Organ Donation Day KFSHRC announces 10 kidney exchange transplants completed in 48 hours
Riyadh: King Faisal Specialist Hospital and Research Centre (KFSHRC) successfully performed 10 kidney exchange transplants over two consecutive days, setting a global record for the highest number of such procedures conducted within a two-day span at a single center, coinciding with World Organ Donation Day on August 13. This milestone reinforces KFSHRC's position as a global leader in organ transplantation. This accomplishment reflects the hospital's high clinical readiness, the seamless coordination of its multidisciplinary medical teams, and its advanced systems for managing donor-recipient matching, alongside its extensive experience in executing complex transplant procedures. All of these factors enable KFSHRC to carry out this type of exchange transplantation with precision and within an exceptionally short timeframe. Paired kidney transplantation is an innovative approach that matches donor–patient pairs for mutual exchange. In this system, each donor gives a kidney to a patient with whom they have no direct relation, while their own relative receives a kidney from another donor. The process significantly improves compatibility rates and offers new hope to patients who face challenges in finding a suitable match within their families. Last year, KFSHRC celebrated a major milestone by completing more than 500 paired kidney transplants since the program was launched in 2011. Since launching its organ transplantation program in 1981, the hospital has successfully performed over 5,000 kidney transplants, placing it among an elite group of global transplant centers. In 2024, the hospital conducted 80 pediatric kidney transplants, the highest annual volume reported worldwide. This makes KFSHRC's pediatric kidney transplant program the largest of its kind compared to leading centers in the United States and Europe. This remarkable achievement underscores KFSHRC's commitment to its vision of being the provider of choice for specialized healthcare. By leveraging its skilled workforce, advanced technologies, and the integration of research and clinical programs, the hospital aims to deliver world-class treatment experiences both locally and globally, while enhancing the Kingdom's position as a leader in organ transplantation. KFSHRC has been ranked first in the Middle East and North Africa and 15th globally in the list of the world's top 250 Academic Medical Centers for the second consecutive year and has been recognized as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2024 Brand Finance rankings. Additionally, in the same year, it was ranked among the world's best 250 hospitals and included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine. For more information, visit or contact our media team at mediacoverage@
Web Release
09-07-2025
- Web Release
A Life Rewritten: KFSHRC Treats Rare Disease After 22 Years of Specialized Care
In a rare example of a lifelong bond between a patient and a healthcare institution, King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh has continued to support a patient since infancy, providing 22 years of continuous care for a rare genetic blood clotting disorder, ultimately culminating in a liver transplant—the first of its kind globally for this particular condition. When the early signs of illness appeared during the patient's first months of life, KFSHRC teams raced against time to stabilize her condition. She was diagnosed with a congenital deficiency in plasminogen, a protein essential for dissolving blood clots, resulting in fibrous deposits that posed serious threats to her tissues and organs. The complexity of her case posed both medical and quality-of-life challenges, requiring a comprehensive, multidisciplinary care system. This extended beyond medical treatment to include all facets of life-supporting care. Teams from nursing, nutrition, and information technology joined hematology and transplant specialists to ensure the young girl's well-being. In a reflection on the early days, the patient's father said: 'My daughter suffered from the moment she was born. She cried constantly and couldn't nurse. We lived in continuous worry with no clear answers until God opened a door of hope. Today, thanks to God first, and then to the remarkable healthcare capabilities provided by the Government of the Custodian of the Two Holy Mosques and His Royal Highness the Crown Prince, may God preserve them, we witness our daughter's recovery from this rare disease after two decades of struggle.' Throughout the years of treatment, the patient relied on regular intravenous doses of plasminogen, along with eye drops to reduce the disease's effect on her vision. The annual cost of treatment exceeded 6 million SAR, fully covered by the Saudi government. This reflects the Kingdom's profound commitment to human health and its investment in quality of life even in the most complex medical cases. Dr. Hazzaa Al-Zahrani, Director of Adult Hematology and Stem Cell Transplant Division at KFSHRC Riyadh and the supervising physician, explained that managing the case required a precise and long-term approach to prevent complications and ensure stability. The decision to proceed with a liver transplant came after careful consideration as an extraordinary therapeutic option for an exceptionally rare case. The success of the procedure marked a turning point in her medical journey and a beacon of hope for patients facing similar conditions worldwide. This approach is deeply rooted in the vision of King Faisal Specialist Hospital & Research Centre, which places the patient at the core of every practice and is committed to delivering integrated care where scientific expertise meets human compassion, in line with its mission to serve society at the highest standards. For more information, visit or contact our media team at [email protected]
Arabian Post
26-06-2025
- Arabian Post
Ant Role-Switching Unveils Ancient Social Blueprint
Leafcutter ant colonies, celebrated for their rigid division of labour, have yielded a startling secret: their roles can be rewired with a molecular tweak. Scientists from the University of Pennsylvania orchestrated this transformation using two tiny neuropeptides, shifting defenders into nurses and garden workers into leaf harvesters. The work, published in Cell on 9 June 2025, reveals a mechanism conserved across species, reaching mammals such as naked mole-rats—suggesting a 600‑million‑year‑old evolutionary blueprint guiding social organisation. Research led by Daniel S. Och Penn Integrates Knowledge University Professor Shelley L. Berger focused on the neurochemistry of division of labour in Atta cephalotes, a leafcutter ant species. In these highly structured societies, ants specialise very early, with larger Majors guarding the colony, Media ants gathering leaves, and smaller Minims managing fungal gardens and caring for brood. By altering the levels of crustacean cardioactive peptide and neuroparsin‑A, researchers caused dramatic behavioural shifts: upping CCAP induced gardeners and defenders to start harvesting leaves, while reducing NPA in Majors triggered caregiving instincts. Genetic knockdown and direct peptide injections produced rapid behavioural reassignments, echoed by transcriptomic profiles aligning with the new roles. Media ants treated with CCAP began leaf‑harvesting patterns typical of their subcaste, confirmed by gene‑expression pathways linked to foraging. Similarly, Majors with reduced NPA exhibited brood‑care behaviours and corresponding gene‑expression patterns. ADVERTISEMENT What makes this finding truly remarkable is its cross‑species resonance. Molecular signatures that defined ant behaviour corresponded with those observed in Heterocephalus glaber, the naked mole‑rat—another eusocial species with task‑based worker castes. The parallel suggests that neuropeptide‑driven social regulation may trace back to a common ancestor deep in evolutionary history. 'We were amazed to see the apparent similarity of gene regulation between nurses and foragers of ants compared to naked mole‑rat mammals,' Berger said, noting that these parallels were unexpected given the vast evolutionary gulf. The study also hints at deeper biological links, particularly regarding insulin signalling and longevity. Leafcutter ant expression patterns showed interplay with insulin pathways previously associated with lifespan control. Naked mole‑rats are known for exceptional longevity, often living beyond 37 years—almost unheard of in rodents—and for their cancer resistance and negligible ageing. Members of Berger's team, including Michael B. Gilbert and Karl M. Glastad, emphasised the role of these neuropeptides as modulators rather than executors of behaviour. Their study, based on rigorous gene expression analyses from both ants and naked mole‑rats, pointed to a convergent evolution model: similar molecular tools repurposed by different species to achieve comparable social complexity. Behavioural plasticity within ant castes was previously explored by examining epigenetic factors and brain structure. Yet, this experiment demonstrates that acute chemical manipulation can override morphological predispositions, offering a dramatic proof of role reversibility in one of nature's most disciplined societies. The findings imply latent flexibility—ants may be much more dynamic in their roles than previously believed. Experts note that while role switching in ants may feel ethically distant, the insights have broader ramifications. Neuropeptides are key regulators in diverse taxa, humans included. For instance, oxytocin in humans influences parental care; the ant study opens questions about universal behavioural circuits shaped by peptides. A deeper understanding of these molecular circuits could eventually inform approaches to social behaviour disorders or age‑related decline. However, some caution that translating findings from invertebrates and subterranean rodents to humans is premature. Neuropeptide systems and brain architectures vary widely. Moreover, nudging behaviour with peptide injections in controlled lab settings does not equate to social engineering in complex natural environments. Still, the implications are profound. The discovery of CCAP and NPA as behavioural switches not only rewrites our understanding of ant societies but also challenges our notions of how ancient molecular codes govern social life. It invites a reevaluation of social evolution, suggesting that similar neurochemical pathways could underlie task allocation in humans, mammals, insects—and maybe even further back in the tree of life.
